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Effects of stroke on changes in heart rate
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Yao-Peng Hsieh4,6,7* and Hung-Chun Chen2,11
Abstract
Background: Stroke and low heart rate variability (HRV) are both associated with an unfavorable prognosis in
hemodialysis patients. The relationship between stroke and changes in HRV during hemodialysis remains unclear.
Methods: This study measured differences between predialysis and postdialysis HRV (△HRV) in 182 maintenance
hemodialysis patients, including 30 patients with stroke, to assess changes in HRV during hemodialysis, and also to
compare results to 114 healthy controls.
Results: All predialysis HRV measurements had no differences between stroke patients and those without stroke,
but were lower than healthy controls. Postdialysis very low frequency (VLF) (P < 0.001), low frequency (LF) (P = 0.001),
total power (TP) (P < 0.001) and the LF/high frequency (HF) ratio (P < 0.001) increased significantly relative to predialysis
values in patients without stroke, whereas postdialysis HRV did not increase in stroke patients. After multivariate
adjustment, dialysis vintage was negatively associated with△VLF (β = -0.698, P = 0.046),△LF (β = -0.931, P = 0.009),
and△TP (β = -0.887, P = 0.012) in patients without stroke. Serum intact parathyroid hormone (β = -0.707, P = 0.019)
was negatively associated with △LF. Total cholesterol (β = -0.008, P = 0.001) and high sensitivity C-reactive protein
(β = -0.474, P = 0.012) were inversely correlated with the △LF/HF ratio in patients without stroke.
Conclusion: HRV in hemodialysis patients is lower than in the general population. Increase in△HRV was observed in
hemodialysis patients without stroke but not in stroke patients. This result suggests suppressed autonomic nervous
reactions against volume unloading during hemodialysis, which might contribute to unfavorable outcomes in
hemodialysis patients but even more so in those with prior stroke. Nephrologists should notice the importance
of △HRV especially in high-risk patients.
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Background
End-stage renal disease (ESRD) has been recognized as a
major public health problem worldwide. ESRD shares
many traditional cardiovascular risk factors with cardio-
vascular disease (CVD), such as aging, hypertension, dia-
betes, and dyslipidemia [1]. CVD is the leading cause of
death in patients with ESRD [2]. Among patients with
CVD, the prevalence and incidence of stroke are drastic-
ally higher in dialysis patients than in the general popu-
lation and patients with non-dialyzed chronic kidney
disease (CKD), and are associated with an unfavorable
prognosis [3–6]. The pathophysiological mechanisms
mediating the poor outcomes of stroke in patients with
ESRD remain unclear. However, these mechanisms ap-
pear to be related to an interaction between traditional
and CKD-related nontraditional risk factors, as well as
to certain characteristics unique to dialysis therapy, in-
cluding uremic milieu, endothelial dysfunction, oxidative
stress, drastic hemodynamic changes, and arterial stiff-
ness [7]. Identifying high-risk individuals and developing
risk stratification methods to initiate aggressive treat-
ment interventions and improve outcomes for ESRD
patients are clinically crucial.
Spectral analysis of heart rate variability (HRV) has
been used as a noninvasive tool for accessing changes in
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the activity of the autonomic nervous system. HRV
measurement provides prognostic and risk-stratification
value for various populations, including patients under-
going chronic hemodialysis therapy [8–12]. Prior studies
have shown that low baseline predialysis HRV is associ-
ated with adverse CVD outcomes and mortality in pa-
tients with ESRD [10–12]. However, change in HRV
during hemodialysis appears to be a stronger predictor
than predialysis HRV [13]. Although stroke is highly
prevalent with unfavorable outcomes in hemodialysis
patients, the relationship between stroke and the effects
of hemodialysis on autonomic regulation measured by
HRV remains unclear. In addition, the factors contribu-
ting to changes in HRV during hemodialysis are not
well known. Therefore, the present study investigated
the relationship between stroke and HRV, and to fur-




The study protocol was approved by the Institutional
Review Board of Kaohsiung Medical University Hospital.
Informed consent was obtained in written form from pa-
tients and controls, and all clinical investigations were
conducted according to the principles of the Declaration
of Helsinki. All patients and controls gave consent for the
publication of their information.
Study patients and design
The study was conducted at the dialysis unit in a re-
gional hospital in Taiwan. All patients in this hospital
who were receiving routine hemodialysis treatment three
times a week were included, excluding those receiving
hemodialysis treatment at night. Patients with an im-
planted cardiac pacemaker or a history of atrial fibrillation
were also excluded. Ultimately, 182 patients (81 male and
101 female) were enrolled in the study from May 2012 to
July 2012.
To compare our HRV results for hemodialysis patients
with the results for individuals without hemodialysis
treatment, 114 controls (41 male and 73 female; mean
age 54.5 ± 8.8 years) were recruited from the outpatient
department of the hospital and general community.
Among controls, 11 (9.6%) were with a history of dia-
betes, and 22 (19.3%) subjects were with a history of
hypertension. The volunteer controls were all screened
carefully to ensure they had no clinical history of stroke
or on dialysis therapy, nor any manifestations of nervous
system, cardiac, or pulmonary disease. The exclusion
criteria included major forms of concurrent cardiac dis-
ease, such as atrial fibrillation, congestive heart failure,
cardiomyopathy and previous myocardial infarction, as
well as history of stroke, through a comprehensive
interview and history taking, 12-lead electrocardiogram
(ECG), and echocardiography.
Hemodialysis treatment
All patients received conventional thrice-weekly hemo-
dialysis treatment by using Toray 321 machines (Toray
Medical Company, Tokyo, Japan). Each hemodialysis
session was conducted for 3 to 4 h by using a dialyzer with
blood flow rates ranging 250–300 mL/min and a dialysate
flow rate of 500 mL/min.
Definition of stroke
Stroke was defined as an episode of acute neurogenic
dysfunction presumed to be caused by ischemia or
hemorrhage, persisting for more than 24 h or until death
[14]. The diagnosis of stroke was verified by patients’
brain imaging of computer tomography or magnetic
resonance imaging and by evidence from the patients’
medical records.
Electrocardiogram signal processing
Detailed procedures for the measurement of HRV have
been reported previously [15–17]. In brief, a pericardial
ECG was taken for 5 min before hemodialysis and after
hemodialysis during the day (between 8 a.m. and 5 p.m.)
with the patient lying quietly and breathing normally in
a supine position for at least 10 min. ECG signals were
recorded using an HRV analyzer (SS1C, Enjoy Research,
Taipei, Taiwan) and an analog-to-digital converter with a
sampling rate of 256 Hz. Digitized ECG signals were
analyzed on-line and were simultaneously stored on a
hard disk for off-line verification. Signal acquisition,
storage, and processing were performed on an IBM-
compatible portable personal computer. The computer
algorithm identified each QRS complex and rejected
each ventricular premature complex and noise according
to its likelihood in a standard QRS template.
HRV frequency domain analysis
Frequency domain analysis was performed using a non-
parametric method of fast Fourier transformation (FFT).
The direct current component was deleted, and a
Hamming window was used to attenuate the leakage
effect [18]. For each time segment (288 s; 2048 data
points), our algorithm estimated the power spectrum
density based on FFT. The resulting power spectrum
was corrected for attenuation resulting from the sam-
pling and the Hamming window. The power spectrum
was subsequently converted into standard frequency do-
main measurements as defined previously [18], including
very low frequency (VLF) (0.003–0.04 Hz), low fre-
quency (LF) (0.04–0.15 Hz), and high frequency (HF)
(0.15–0.40 Hz), as well as the LF/HF ratio. LF was nor-
malized by the percentage of total power (TP) in order
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to determine the sympathetic influence on HRV. A simi-
lar procedure was applied to HF, which is mediated pre-
dominantly by vagal activity. In addition, TP of the
spectrum of ≤ 0.40 Hz was calculated. The values calcu-
lated from each power spectrum, including VLF, LF, HF,
TP, and the LF/HF ratio, were expressed in natural loga-
rithmic form to obtain a normal distribution [15].
Collection of demographic, medical, and laboratory data
Demographic and medical data including age, sex, and
comorbid conditions were obtained from medical re-
cords and interviews with patients. The body mass index
was calculated as the weight in kilograms divided by the
square of height in meters. Venous blood was collected
after an overnight fast for measuring various biomarkers
by using an autoanalyzer (Roche Diagnostics GmbH, D-
68298 Mannheim COBAS Integra 400). Serum intact
parathyroid hormone (iPTH) concentration was evalu-
ated using a commercially available two-sided immunor-
adiometric assay (CIS Bio International, France). Blood
samples were obtained within 1 month of study enroll-
ment. Kt/V was evaluated as a marker of dialysis effi-
ciency and determined using the Gotch procedure [19].
Ultrafiltration percentage was calculated as the difference
between predialysis and postdialysis weight divided by
predialysis weight. Cardiothoracic ratio was measured on
chest x-ray.
Statistical analysis
Statistical analysis was performed using SPSS version
17.0 (SPSS Inc., Chicago, IL, USA) for Windows. Data
are expressed as percentages, mean ± standard deviation,
or mean ± standard error of the mean for HRV measure-
ment values, or median (25th–75th percentile) for dialysis
vintage, triglycerides, high-sensitivity C-reactive protein
(hs-CRP), and iPTH levels. The differences between
groups were analyzed using the Chi-square test for
categorical variables and using the independent t-test
for continuous variables with approximately-normal
distribution, or using the Mann–Whitney U test for
continuous variables with skewed distribution. The
paired t-test was used to compare HRV measurements
before and after hemodialysis. We further examined
whether stroke was associated with changes in HRV
measurements by using an analysis of covariance
(ANCOVA) after multivariate adjustment for age, sex,
current smoking habits, diabetes, hypertension, coron-
ary artery disease, ultrafiltration percentage, cardio-
thoracic ratio > 0.5, log-transformed hs-CRP, and use
of angiotensin converting enzyme (ACE) inhibitors or
angiotensin II receptor blockers (ARBs), beta-blockers,
and calcium channel blockers. Changes in HRV mea-
surements (△HRV) were defined as postdialysis HRV
values minus predialysis HRV values. Multiple forward
linear regression analysis was used to identify the fac-
tors associated with △HRV. A difference was considered
significant if the P < 0.05.
Results
A total of 182 maintenance hemodialysis patients and
114 controls were enrolled and analyzed in this study.
The mean age of the hemodialysis patients and controls
were 61.2 ± 11.3 years and 54.5 ± 8.8 years, respectively.
Table 1 shows a comparison of HRV measurements
between the hemodialysis patients and controls. Com-
pared with those for the controls, the HRV measure-
ments for hemodialysis patients were all significantly
lower, except for the LF/HF ratio. In the linear regres-
sion analysis, after adjustment for age, sex, diabetes
mellitus, hypertension, stroke and cardiovascular disease,
hemodialysis had negative associations with all HRV
parameters, except for the LF/HF ratio.
Among the 182 hemodialysis patients, thirty patients
were verified with stroke (including 27 patients with prior
ischemic stroke and 3 patients with prior hemorrhagic
stroke). None of these patients were with acute state of
stroke. Table 2 presents a comparison of baseline charac-
teristics between hemodialysis patients with and without
stroke. Compared with patients without stroke, stroke
patients were more likely to have an older age, a shorter
dialysis vintage, a higher prevalence of diabetes mellitus,
hypertension, and coronary artery disease, a higher systolic
blood pressure, lower serum albumin and creatinine levels,
and a higher prevalence of cardiothoracic ratio > 0.5. All
measurements of predialysis HRV parameters in stroke
patients (VLF, LF, HF, TP, and the LF/HF ratio) were not
significantly different from those in patients without
stroke.
Effects of hemodialysis on HRV
Table 3 shows the changes in HRV measurements after
hemodialysis therapy. Compared with predialysis HRV
values, postdialysis HRV, including VLF (P < 0.001), LF
(P = 0.001), TP (P < 0.001) and the LF/HF ratio (P < 0.001),
increased significantly after hemodialysis in patients
without stroke. By contrast, no significant changes in









VLF (ln ms2) 4.1 ± 0.1 6.0 ± 0.1 <0.001
LF (ln ms2) 2.3 ± 0.3 5.1 ± 0.1 <0.001
HF (ln ms2) 2.2 ± 0.3 5.0 ± 0.1 <0.001
TP (ln ms2) 4.7 ± 0.1 6.7 ± 0.1 <0.001
LF/HF ratio [ln (ratio)] 0.08 ± 0.09 0.18 ± 0.07 0.405
Abbreviations: HRV heart rate variability, VLF very low frequency, LF low frequency,
HF high frequency, TP total power
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postdialysis HRV measurements relative to the predialysis
values were observed for stroke patients.
We further performed ANCOVA to examine the
main effect of stroke on HRV after multivariate adjust-
ment for age, sex, current smoking habits, diabetes,
hypertension, coronary artery disease, ultrafiltration
percentage, cardiothoracic ratio > 0.5, log-transformed
hs-CRP, and use of ACE inhibitors or ARBs, beta-
blockers, and calcium channel blockers. Our analysis
revealed that hemodialysis in patients without stroke
were independently associated with an increase in post-
dialysis HRV, including VLF (P = 0.010), LF (P = 0.001),








Age (years) 61.2 ± 11.3 60.4 ± 11.7 65.3 ± 8.4 0.009
Male gender (%) 44.5 45.4 40.0 0.689
Dialysis vintage (years) 5.9 (2.3–10.2) 6.6 (2.8–10.8) 2.8 (0.6–6.7) 0.001
Diabetes mellitus (%) 46.2 38.2 86.7 <0.001
Hypertension (%) 62.6 58.6 83.3 0.012
Coronary artery disease (%) 27.5 18.4 73.3 <0.001
Current smoking habits (%) 4.4 3.3 10.0 0.127
Systolic blood pressure (mmHg) 152.7 ± 26.5 150.2 ± 25.1 165.7 ± 30.2 0.004
Diastolic blood pressure (mmHg) 81.6 ± 14.3 81.8 ± 14.2 80.2 ± 14.8 0.573
Body mass index (kg/m2) 23.8 ± 3.4 23.9 ± 3.4 23.4 ± 3.6 0.520
Laboratory parameters
Albumin (g/L) 38.4 ± 3.0 38.6 ± 2.9 37.2 ± 3.1 0.019
Fasting glucose (mg/dL) 119.2 ± 51.8 114.9 ± 43.0 142.0 ± 82.0 0.099
Triglycerides (mg/dL)a 131 (92–210) 127 (94–207) 153 (86–215) 0.314
Total cholesterol (mg/dL)b 182.5 ± 42.0 182.1 ± 41.8 184.6 ± 43.9 0.773
Hemoglobin (g/dL) 10.2 ± 1.1 10.3 ± 1.1 10.1 ± 1.0 0.443
Creatinine (mg/dL) 9.7 ± 2.1 9.9 ± 2.1 8.6 ± 1.7 0.004
Calcium (mg/dL)c 9.4 ± 1.0 9.4 ± 1.0 9.3 ± 1.3 0.707
Phosphorus (mg/dL)d 4.5 ± 1.0 4.4 ± 1.0 4.6 ± 1.1 0.384
iPTH (pg/mL) 351 (187–480) 351 (184–468) 348 (205–576) 0.710
hs-CRP (mg/L) 2.7 (1.0–6.5) 2.6 (1.0–6.6) 2.9 (0.8–6.3) 0.632
Kt/V (Gotch) 1.3 ± 0.2 1.3 ± 0.2 1.4 ± 0.2 0.736
Ultrafiltration percentage (%) 4.2 ± 1.4 4.2 ± 1.4 4.7 ± 1.6 0.060
Cardiothoracic ratio > 0.5 (%) 53.3 47.4 83.3 0.001
Medications
ACE inhibitors or ARBs (%) 16.5 17.1 13.3 0.999
Beta-blockers (%) 17.6 16.4 23.3 0.180
Calcium channel blockers (%) 19.8 19.7 20.0 0.669
Frequency domain HRV parameters
VLF (ln ms2) 4.1 ± 0.1 4.2 ± 0.1 3.6 ± 0.4 0.079
LF (ln ms2) 2.3 ± 0.3 2.6 ± 0.2 0.50 ± 1.27 0.107
HF (ln ms2) 2.2 ± 0.3 2.5 ± 0.2 0.51 ± 1.45 0.176
TP (ln ms2) 4.7 ± 0.1 4.8 ± 0.1 4.2 ± 0.4 0.054
LF/HF ratio [ln (ratio)] 0.08 ± 0.09 0.09 ± 0.10 -0.02 ± 0.27 0.652
Abbreviations: iPTH intact parathyroid hormone, hs-CRP high sensitivity C-reactive protein, ACE angiotensin converting enzyme, ARB angiotensin II receptor blocker,
HRV heart rate variability, VLF very low frequency, LF low frequency, HF high frequency, TP total power
aFor conversion into SI units (mmol/L): multiply with 0.0114
bFor conversion into SI units (mmol/L): multiply with 0.0259
cFor conversion into SI units (mmol/L): multiply with 0.25
dFor conversion into SI units (mmol/L): multiply with 0.323
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and TP (P = 0.048). No such association was observed
for the LF/HF ratio (Table 4).
Determinants of △HRV in patients without stroke
Table 5 shows the unstandardized coefficient β of △HRV
values, which were significant in patients without stroke,
after adjustment for age, sex, dialysis vintage, current
smoking habits, a history of diabetes, hypertension, and
coronary artery disease, systolic and diastolic blood pres-
sure, body mass index, levels of albumin, fasting glucose,
triglycerides, total cholesterol, hemoglobin, creatinine,
total calcium, phosphorus, iPTH, log-transformed hs-CRP,
Kt/V, ultrafiltration percentage, cardiothoracic ratio > 0.5,
and use of ACE inhibitors or ARBs, beta-blockers, and
calcium channel blockers.
In the multivariate forward analysis, a longer dialysis vin-
tage was negatively associated with△VLF (unstandardized
coefficient β = -0.698, P = 0.046),△LF (unstandardized co-
efficient β = -0.931, P = 0.009), and △TP (unstandardized
coefficient β = -0.887, P = 0.012). A lower iPTH level was
correlated with△LF (unstandardized coefficient β = -0.707,
P = 0.019). Furthermore, the total cholesterol level (unstan-
dardized coefficient β = -0.008, P = 0.001) and hs-CRP level
(unstandardized coefficient β = -0.474, P = 0.012) were in-
versely correlated with the △LF/HF ratio in patients with-
out stroke.
Discussion
In the present study, we investigated the association
between stroke and HRV in hemodialysis patients. All
predialysis HRV measurements in stroke patients were
not significantly different from those in patients without
stroke, but were lower than in the controls. Compared
with predialysis HRV values, all postdialysis HRV mea-
surements, except for HF, significantly increased in pa-
tients without stroke, whereas no increase in postdialysis
HRV was observed in stroke patients. Dialysis vintage,
serum iPTH, total cholesterol, and hs-CRP levels contribu-
ted to changes in△HRV in patients without stroke.
The baseline HRV values were lower in hemodialysis
patients compared with healthy controls in our study,
and this finding was in line with the report by Vita et al
[20]. Although the actual underlying mechanisms remain
uncertain, activation of the renal afferents, structural re-
modeling of the heart and vasculature, as well as im-
paired reflex control of autonomic activity may play
pivotal roles in ESRD patients [21].
HRV has been reported to be suppressed in both
hemorrhagic and ischemic stroke patients [22–24].
Korpelainen et al. [23] demonstrated that, compared
with control subjects, patients had impaired VLF and
LF in the acute phase of ischemic stroke at hemi-
sphere, as well as in the late state of stroke. Previous
studies have demonstrated that baroreflex impairment
occurred in ischemic and hemorrhagic stroke [25, 26].
Impaired baroreflex function might lead to altered car-
diovascular regulation in stroke. Studies of ESRD pa-
tients on dialysis therapy have also shown evidence of
decreased HRV [20, 27]. Renal failure and stroke have
both been associated with impaired autonomic func-
tion. However, the relationship between stroke and
HRV in ESRD patients has not previously been eluci-
dated. In the present study, no significant differences
in predialysis HRV values between hemodialysis pa-
tients with and without stroke were observed. Our
proposed reason for this observation is that HRV in
hemodialysis patients is affected by factors other than
stroke, such as the composition and temperature of
the dialysate [28, 29], and fluid overload levels [30].
Changes in HRV during hemodialysis treatment have
been demonstrated in patients with ESRD [31, 32]. Emer-
ging evidence indicates that the ability of changes in
△HRV is a better predicting factor for unfavorable out-
comes in comparison of predialysis HRV [13]. Although
patients with or without stroke and hemodialysis did not
significantly differ in predialysis HRV, an increase in
△HRV was observed in patients without stroke but not in
patients with stroke. Our HRV results further elucidate
the relationship between stroke and the effects of
hemodialysis on autonomic nervous system regulation. In
patients without stroke, postdialysis values of VLF, LF, TP,
Table 3 Comparison of predialysis and postdialysis HRV parameters
in hemodialysis patients with and without stroke
Frequency domain Without stroke With stroke
HRV parameters Predialysis Postdialysis Predialysis Postdialysis
VLF (ln ms2) 4.2 ± 0.1 4.8 ± 0.1† 3.6 ± 0.4 2.8 ± 1.0
LF (ln ms2) 2.6 ± 0.2 3.4 ± 0.3* 0.50 ± 1.27 -0.17 ± 1.62
HF (ln ms2) 2.5 ± 0.2 2.9 ± 0.3 0.51 ± 1.44 0.69 ± 1.47
TP (ln ms2) 4.8 ± 0.1 5.5 ± 0.1† 4.2 ± 0.4 4.3 ± 0.4
LF/HF ratio [ln (ratio)] 0.09 ± 0.10 0.47 ± 0.08† -0.02 ± 0.27 0.02 ± 0.27
*P-value < 0.05 compared with predialysis HRV
†P-value < 0.001 compared with predialysis HRV
Abbreviations are the same as in Table 1
Table 4 Multivariate adjustment for main effects of stroke on
△HRV parameters in hemodialysis patients
△HRV parameters Parameter estimate (95% CI) P-value
△VLF (ln ms2) 1.917 (0.463, 3.370) 0.010
△LF (ln ms2) 3.246 (1.291, 5.322) 0.001
△TP (ln ms2) 0.790 (0.009, 1.572) 0.048
△LF/HF ratio 0.513 (-0.140, 1.165) 0.122
Values expressed as parameter estimates and 95% confidence interval (CI)
Covariates in the multivariate model included age, sex, current smoking habits,
a history of diabetes, hypertension, stroke, and coronary artery disease,
ultrafiltration percentage, cardiothoracic ratio > 0.5, log-transformed hs-CRP
and use of ACE inhibitors or ARBs, beta-blockers, and calcium channel blockers
Huang et al. BMC Nephrology  (2017) 18:90 Page 5 of 8
and the LF/HF ratio increased significantly relative to the
predialysis values, suggesting a shift toward sympathetic
predominance of sympatho-vagal balance by volume
unloading during hemodialysis. These findings are com-
parable with a study by Tong and Hou [32]. By contrast,
there were no significant differences between predialysis
and postdialysis HRV values in stroke patients. This obser-
vation implies an autonomic cardiovascular dysregulation
and impaired sympathetic reaction against fluid removal
during hemodialysis treatment in stroke patients. The
pathophysiological mechanisms of such dysfunction re-
main unclear. Accumulating evidence suggests that the
central autonomic network, especially the insular cortex,
seems to play a key role in modulating the baroreflex
function [33]. Furthermore, baroreflex impairment has
been independently associated with unfavorable outcomes
after stroke [26, 34].
The process of ultrafiltration during hemodialysis re-
duces circulating volume and arterial pressure, which
could be sensed by baroreceptors and trigger cardiac
sympathetic response. In the present study, we found
that a longer dialysis vintage was inversely associated with
increases in postdialysis VLF, LF, and TP, relative to the pre-
dialysis values in hemodialysis patients without stroke. It
suggests that the effect of fluid removal on HRV might be
blunted as dialysis vintage becomes longer. Chrapko et al.
[35] evaluated the cardiac sympathetic nervous system
function by using iodine-123 meta-iodo-benzylguanidine
(123I-mIBG) myocardial uptake in 36 hemodialysis patients.
Their results showed that patients with longer duration of
hemodialysis had impaired function of the cardiac sympa-
thetic system, thus supporting our hypothesis. The cardiac
sympathetic response might deteriorate with increased dur-
ation of hemodialysis. This phenomenon is also similar to
the work by Tamura et al. [36], which demonstrated that a
longer duration of hemodialysis was associated with de-
creased HRV.
Secondary hyperparathyroidism is common in hemo-
dialysis patients and may play a role in dysfunction of
the autonomic nerve system. Polak et al. [37] reported
low LF and HF in 40 hemodialysis patients with high
serum levels of iPTH, indicating deterioration in auto-
nomic activity. Increase in iPTH may cause endothelial
dysfunction and vascular calcification, leading to enhanced
coronary risk. Furthermore, Zhang et al. [38] found that
serum level of iPTH was significantly correlated with de-
creased HRV, and parathyroidectomy might reverse the
cardiovascular risk in CKD stage 5 patients. Consistent
with previous studies, we found that higher iPTH levels
were negatively associated with increased postdialysis LF
in patients without stroke. Controlling iPTH levels might
help to increase postdialysis HRV in such patients.
In addition, our results show that hypercholesterolemia
was negatively associated with the △LF/HF ratio in pa-
tients without stroke. Several studies have examined the
relationship between dyslipidemia and HRV in the general
or ESRD population. For example, Christensen et al. [39]
reported an association between hypercholesterolemia
and low HRV. The association between dyslipidemia and
low HRV is not fully understood. In both animal and
human studies, the autonomic nervous system has been
reported to participate in the regulation of cholesterol syn-
thesis [40, 41]. Shanygina et al. [41] showed that vagotomy
was associated with increased levels of total and low-
density lipoprotein cholesterol in an animal model. Hence,
impaired sympatho-vagal balance might be associated
with dyslipidemia. Our findings for hemodialysis patients
without stroke are in line with those of prior research.
Table 5 Determinants of△HRV parameters of hemodialysis patients without stroke
△HRV parameters Multivariate (Forward)
Unstandardized coefficient β (95% CI) P-value
△VLF
Dialysis vintage (log per 1 year) -0.698 (-1.383,-0.013) 0.046
△LF
Dialysis vintage (log per 1 year) -0.931 (-1.622, -0.240) 0.009
iPTH (log per 1 pg/mL) -0.707 (-1.298, -0.117) 0.019
△TP
Dialysis vintage (log per 1 year) -0.887 (-1.571, -0.202) 0.012
△LF/HF ratio
Total cholesterol (per 1 mg/dL) -0.008 (-0.013, -0.003) 0.001
hs-CRP (log per 1 mg/L) -0.474 (-0.844, -0.105) 0.012
Values expressed as unstandardized coefficient β and 95% confidence interval (CI)
Covariates in the multivariate model included age, sex, dialysis vintage, current smoking habits, a history of diabetes, hypertension, and coronary artery disease,
systolic and diastolic blood pressure, body mass index, albumin, fasting glucose, triglycerides, total cholesterol, hemoglobin, creatinine, total calcium, phosphorus,
iPTH, log-transformed hs-CRP, Kt/V, ultrafiltration percentage, cardiothoracic ratio > 0.5, use of ACE inhibitors or ARBs, beta-blockers, and calcium channel blockers
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Treating dyslipidemia in such patients might have a po-
tential role of improving HRV. Moreover, we found that
hs-CRP level was inversely correlated with the △LF/HF
ratio in patients without stroke. Autonomic dysregulation
might be worse in patients with inflammation. This find-
ing is comparable with the report by Chandra et al. [42] in
CKD stages 3–5 patients. As inflammation is an important
risk factor for unfavorable outcomes, therapeutic interven-
tions targeting inflammation need to be developed in
clinical trials. Further study is warranted to understand
the pathways responsible for these observed associations.
There were several limitations in the current study.
First, the study was a cross-sectional design with inher-
ent weaknesses including unclear causal relationships
and a lack of long-term observation of outcomes. Sub-
jects of controls should be sex, age, and comorbidity-
matched to compare with study patients. Second, a 24-h
Holter ECG for HRV measurements would provide sub-
stantially more data. A previous report, however, indi-
cated that 5 min is sufficient for short-term HRV
analysis [43]. Third, the number of study patients was
relatively small. The FFT method for HRV analysis
might not be perfectly accurate, and using a robust
period detection may have better performance [44].
Moreover, participants in this study are survivors of
stroke, and thus at risk for survivor bias. These results
might not be generalizable to all hemodialysis patients
who experienced stroke. Changes in serum glucose
during hemodialysis, markers of fluid overload as well as
cardiac function may affect HRV, and should be considered
in the further studies. A future large-scale prospective in-
vestigation including non-linear parameters of HRV and
assessing baroreflex using heart rate and blood pressure
variability is necessary.
Conclusions
Baseline predialysis HRV did not significantly differ be-
tween hemodialysis patients with stroke and those without
stroke, but was lower than controls. An increase in
△HRV was demonstrated in patients without stroke but
was not observed in stroke patients after hemodialysis.
The results suggest a suppressed autonomic nervous re-
action against volume unloading during hemodialysis,
which might be a plausible contributing factor of un-
favorable outcomes in stroke patients. Long dialysis
vintage, high iPTH levels, high total cholesterol, and
high hs-CRP levels were associated with a lesser degree
of HRV increase after hemodialysis in patients without
stroke. As the ability of increase in △HRV is a novel
predictor of outcomes in hemodialysis patients, physi-
cians and nephrologists should not only notice the im-
portance of predialysis HRV, but also the changes in
postdialysis HRV in high-risk patients.
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